HER2異常等の低頻度の分子異常を有する非小細胞肺癌の臨床病理学的特徴を明らかにするための前向き観察研究（HER2-CS Study）と標準化学療法後再発・増悪または標準化学療法不応性のHER2陽性非小細胞肺癌患者を対象としたトラスツズマブエムタンシン（遺伝子組換え）の第2相試験

ID	53537
Sort Key	9
Title Alternative	A prospective cohort study to define the clinical and pathological features of lung cancers harboring HER2 gene aberrations (the HER2-CS Study) and a phase II study of trastuzumab emtansine (recombinant) in patients with HER2-positive non-small cell lung cancer who recurred, progressed after standard chemotherapy, or were primarily refractory to standard chemotherapy
FullText URL	127_127.pdf 1.69 MB
Author	Kiura, Katsuyuki ORCID Kaken ID publons researchmap Hotta, Katsuyuki Kaken ID publons researchmap Sato, Akiko Ohashi, Kadoaki ORCID Kaken ID researchmap Ninomiya, Takashi Minnami, Daisuke Tabata, Masahiro Kaken ID researchmap Kubo, Toshio Kaken ID researchmap Kato, Yuka Kaken ID Hirata, Taizo
Keywords	臨床研究中核病院国立研究開発法人日本医療研究開発機構文部科学省橋渡し研究加速ネットワークプログラム HER2-CS study trastuzumab emtansine
Note	特集(Feature Articles)
Publication Title	岡山医学会雑誌
Published Date	2015-08-03
Volume	volume127
Issue	issue2
Publisher	岡山医学会
Publisher Alternative	Okayama Medical Association
Start Page	127
End Page	132
ISSN	0030-1558
NCID	AN00032489
Content Type	Journal Article
Related Url	isVersionOf https://doi.org/10.4044/joma.127.127
OAI-PMH Set	岡山大学
language	Japanese
Copyright Holders	Copyright (c) 2015 岡山医学会
File Version	publisher
Refereed	True
DOI	10.4044/joma.127.127
NAID	130005096256
Eprints Journal Name	joma